We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanoparticle-Based Hydrogel Liquefies Under Pressure for Delivery by Syringe

By LabMedica International staff writers
Posted on 04 Mar 2015
A hydrogel that liquefies under pressure but reforms as a gel when the pressure is released has been recruited as a delivery system for both hydrophobic and hydrophilic anticancer agents.

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) created the hydrogel by mixing PEG-PLA (polyethylene glycol- polymerized lactic acid) nanoparticles with polymeric cellulose. More...
Each polymer chain formed weak bonds with a number of nanoparticles, producing a loosely woven lattice of polymers and nanoparticles. As each attachment point was fairly weak, the bonds disassociated under the mechanical stress of being injected through a syringe. Once the shear forces had abated, the polymers and nanoparticles formed new attachments with different partners, returning the conglomerate to the gel form.

The composition of the gel allowed it to be loaded simultaneously with two different types of drugs. The PEG-PLA nanoparticles had an inner core capable of carrying small-molecule hydrophobic drugs, which include many chemotherapy agents. At the same time, the cellulose polymer, which existed in aqueous solution, could transport hydrophilic molecules such as proteins, including antibodies and growth factors.

A detailed description of the hydrogel as well as results of an in vivo experiment in which gels injected under the skin of mice survived and successfully released two drugs—one hydrophobic and one hydrophilic—over a period of several days, was published in the February 19, 2015, online edition of the journal Nature Communications.

“We are working with really simple materials,” said contributing author Dr. Mark Tibbitt, a postdoctoral researcher at the Massachusetts Institute of Technology. “They do not require any advanced chemical functionalization. Now you have a gel that can change shape when you apply stress to it, and then, importantly, it can re-heal when you relax those forces. That allows you to squeeze it through a syringe or a needle and get it into the body without surgery.”

Related Links:

Massachusetts Institute of Technology



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automatic CLIA Analyzer
Shine i6000
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.